Praxis Precision Medicines (PRAX) Short-term Investments (2024 - 2026)

Praxis Precision Medicines' Short-term Investments history runs 3 years deep, the most recent figure standing at $250.5 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 54.25% year-over-year to $250.5 million in Q1 2026; TTM through Mar 2026 was $250.5 million, a 54.25% increase from a year earlier, with the FY2025 full-year figure at $242.0 million, up 36.57% from the prior year.
• Short-term Investments improved to $250.5 million in Q1 2026 per PRAX's latest filing, from $242.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $250.5 million in Q1 2026 and bottomed at $55.4 million in Q1 2024.
• The 3-year median for Short-term Investments is $177.2 million (2024), against an average of $171.6 million.
• Biggest YoY gain for Short-term Investments was 192.99% in 2025; the steepest drop was 37.56% in 2025.
• Year by year, Short-term Investments stood at $177.2 million in 2024, then jumped by 36.57% to $242.0 million in 2025, then increased by 3.52% to $250.5 million in 2026.
• Per Business Quant, the three latest PRAX Short-term Investments figures stand at $250.5 million (Q1 2026), $242.0 million (Q4 2025), and $117.6 million (Q3 2025).